Metastatic Triple Negative Breast Cancer: Overcoming Challenges in Diagnosis Treatment and Management - Episode 5

Managing Adverse Events in Patients Receiving Later Line Systemic Therapy for Metastatic TNBC

October 26, 2023
Nour Abuhadra, MD

Dr. Noor Abuhadra discusses managing adverse events in patients receiving TRODELVY (sacituzumab govitecan), a later-line systemic therapy for metastatic triple-negative breast cancer. Shay Elkins, a patient, shares her experience with significant side effects including diarrhea, low white blood cell counts, and hair loss, while Dr. Abuhadra emphasizes the need for proactive management of these issues to maximize treatment time and maintain quality of life.

EP. 1: Background on Metastatic Triple Negative Breast Cancer
EP. 2: Initial Treatment Options for Metastatic TNBC
EP. 3: Second-Line Therapy for Metastatic TNBC
EP. 4: ASCENT Study: Impact of Sacituzumab Govitecan on Metastatic TNBC
Now Viewing
EP. 5: Managing Adverse Events in Patients Receiving Later Line Systemic Therapy for Metastatic TNBC
EP. 6: Overcoming Barriers to Treatment Access and Reimbursement

Related Content:

Metastatic Triple Negative Breast Cancer: Overcoming Challenges in Diagnosis Treatment and ManagementCURE Connections Breast Cancer
Imlunestrant-Based Therapy May Improve Survival Without Progression in Advanced Breast Cancer
Local Recurrence Lowered With Immediate Surgery in Elderly Patients With Breast Cancer
Lynparza Continues to Benefit in BRCA1/2+, HER2- Breast Cancer